The proto-oncogene AKT (also known as PKB) is activated in many human cancers, mostly owing to loss of the
PTEN tumour suppressor
1. In such tumours, AKT becomes enriched at cell membranes where it is activated by phosphorylation. Yet many targets inhibited by phosphorylated AKT (for example, the FOXO transcription factors) are nuclear; it has remained unclear how relevant nuclear phosphorylated AKT (pAKT) function is for tumorigenesis. Here we show that the PMLtumour suppressor prevents cancer by inactivating pAKT inside the nucleus. We find in a mouse model that
Pml loss markedly accelerates tumour onset, incidence and progression in
Pten-heterozygous mutants, and leads to female sterility with features that recapitulate the phenotype of
Foxo3a knockout mice
2. We show that
Pml deficiency on its own leads to tumorigenesis in the prostate, a tissue that is exquisitely sensitive to pAkt levels, and demonstrate that Pml specifically recruits the Akt phosphatase PP2a as well as pAkt into Pml nuclear bodies. Notably, we find that
Pml-null cells are impaired in PP2a phosphatase activity towards Akt, and thus accumulate nuclear pAkt. As a consequence, the progressive reduction in
Pml dose leads to inactivation of Foxo3a-mediated transcription of proapoptotic
Bim and the cell cycle inhibitor
p27kip1. Our results demonstrate that Pml orchestrates a nuclear tumour suppressor network for inactivation of nuclear pAkt, and thus highlight the importance of AKT compartmentalization in human cancer pathogenesis and treatment.